GENE ONLINE|News &
Opinion
Blog

Antisense Oligonucleotides
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
AstraZeneca, Ionis Close $3.5+ Billion Deal for Rare Protein Misfolding Disorder
2021-12-30
Wave Initiates Trial of Investigational Antisense Oligonucleotide Against Huntington’s Disease
2021-09-13
R&D
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
2020-08-17
Part II Highlights of BIO Asia-Taiwan 2020 (Day 1): Global Trends in Biotech and the Impact of COVID-19
2020-07-23Partner
Spotlight: Roche’s SMA Drug, Risdiplam Makes Strong Case for Regulatory Approval
2020-07-05
R&D
Biogen’s SMA Drug, Spinraza Continues to Show Benefits in Pre-Symptomatic Patients
2020-06-14
The Rejuvenated Promise of RNA Therapeutics
2020-01-07
LATEST
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top